SYRE

Spyre Therapeutics, Inc.

NasdaqGSUSDEQUITY DELAYED

106.28

▼ 1.51 (1.40%)

MARKET · —

Price

Open

107.80

Prev close

107.79

Day high

110.00

Day low

105.71

Volume

909.35K

Market cap

—

P/E (TTM)

—

52W range

14.51 – 110.18

Trailing performance

Price return · vs SPY

Returnvs SPY

+2.76% +4.1%

+6.50% +2.8%

+43.29% +40.2%

+146.45% +135.4%

YTD

+225.06% +212.8%

+551.31% +531.3%

+821.99% +747.8%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

105.33

+0.91% from price

SMA 20

103.18

+3.21% from price

SMA 50

96.96

+9.83% from price

SMA 100

82.79

+28.37% from price

SMA 200

58.47

+82.12% from price

EMA 12

105.17

+1.06% from price

EMA 26

102.06

+4.14% from price

EMA 50

95.96

+10.76% from price

RSI (14)

57.8

Neutral

MACD (12,26,9)

3.11

Hist -0.03

ATR (14)

5.54

5.20% of price

Realised vol 30D

57.4%

Annualised

Bollinger upper

110.20

20, 2σ

Bollinger lower

96.15

20, 2σ

50 / 200 cross

Golden

96.96 vs 58.47

Trend bias

Above 200

+82.12%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.86

More volatile than market

Correlation to SPY

0.35

Loosely linked

Realised vol 30D

57.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-14.7%

Peak to trough

Max drawdown 5Y

-98.7%

Peak to trough

ATR 14

5.54

5.20% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 106.28

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

SYRE · links out to the publisher

This Stock’s Already Up Nearly 600% Over the Past Year Barchart · 3d ago Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing MT Newswires · 11d ago Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa MT Newswires · 12d ago Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? Simply Wall St. · 12d ago Spyre Therapeutics Announces Grants of Inducement Awards GlobeNewswire · 15d ago Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know Motley Fool · 16d ago A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know Motley Fool · 16d ago Spyre Therapeutics Insider Sold Shares Worth $1,432,705, According to a Recent SEC Filing MT Newswires · 16d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.